Sidley Represents Respira in Its Option to Be Acquired by Gossamer Bio
September 30, 2025
联系方式
随时了解最新情况
Sidley represented Respira Therapeutics, Inc., a Samsara BioCapital portfolio company, in its agreement granting an option to Gossamer Bio, Inc. (Nasdaq: GOSS) to acquire the company. Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed therapy for use in pulmonary hypertension.
The Sidley team was led by partner Jason Kropp and counsel Rebecca Nauta (Emerging Companies and Venture Capital), and included Dr. Christian Brause and Andy Lau (Tax); Nicholas Frey (Employee Benefits and Executive Compensation); Lauren Grau (Technology and Life Sciences Transactions); and Ethan McMahon and Margalit Zimand (M&A).